RVNC Revance Therapeutics, Inc.

20.95
-0.25  -1.18%
Previous Close 21.20
Open 21.20
Price To book 3.01
Market Cap 597.39M
Shares 28,515,000
Volume 162,800
Short Ratio 28.66
Av. Daily Volume 164,197

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 2H 2017.
RT002
Plantar fasciitis
Phase 3 endpoints not met June 2016
RT001 - REALISE 1
Lateral Canthal (Crow’s Feet) Lines
Phase 2 full data due 1H 2017.
RT002
Cervical dystonia
Phase 3 data due 4Q 2017.
RT002 - SAKURA
Moderate to severe glabellar (frown) lines

Latest News

  1. Revance Therapeutics to Release Fourth Quarter 2016 Financial Results Monday, February 27, 2017
  2. REVANCE THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
  3. Revance Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : RVNC-US : January 31, 2017
  4. BELMONT Phase 2 Clinical Data to be Presented at IMCAS World Congress 2017
  5. BELMONT Phase 2 Clinical Data to be Presented at IMCAS World Congress 2017
  6. Revance Presents Clinical Data for RT002 Injectable at TOXINS 2017
  7. REVANCE THERAPEUTICS, INC. Files SEC form 8-K, Other Events
  8. REVANCE THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
  9. Revance Provides Clinical Milestones and Financial Outlook for 2017
  10. Revance Therapeutics, Inc. – Value Analysis (NASDAQ:RVNC) : December 15, 2016
  11. Revance Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : RVNC-US : December 14, 2016
  12. REVANCE THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhib
  13. Revance Announces Positive 24-Week Duration of Effect in Interim Results from Phase 2 Cervical Dystonia Trial
  14. Revance Announces Initiation of Subject Dosing in the SAKURA Phase 3 Clinical Program of RT002 Injectable for the Treatment of Glabellar (Frown) Lines
  15. ETFs with exposure to Revance Therapeutics, Inc. : December 2, 2016
  16. Coverage initiated on Revance Therapeutics by Aegis Capital
  17. Revance to Participate in the 28th Annual Piper Jaffray Healthcare Conference
  18. REVANCE THERAPEUTICS, INC. Financials
  19. Revance Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : RVNC-US : November 10, 2016
  20. ETF’s with exposure to Revance Therapeutics, Inc. : November 8, 2016